Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant

We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy. MTX was given at a dose of 8.0 g/m 2 for induction and at a dose of 3.5–8.0 g/m 2...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2009-03, Vol.92 (1), p.65-71
Main Authors: Yang, Seung-Ho, Lee, Kun Soo, Kim, Il Sup, Hong, Jae Taek, Sung, Jae Hoon, Son, Byung Chul, Lee, Sang Won, Hong, Yong-Kil
Format: Article
Language:English
Subjects:
Adult
Aged
Antimetabolites, Antineoplastic - administration & dosage
Biomarkers, Tumor - analysis
Central Nervous System Neoplasms - drug therapy
Central Nervous System Neoplasms - metabolism
Central Nervous System Neoplasms - mortality
Clinical Study - Patient Study
Disease-Free Survival
Dose-Response Relationship, Drug
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - metabolism
Lymphoma, Non-Hodgkin - mortality
Male
Medicine
Medicine & Public Health
Methotrexate - administration & dosage
Middle Aged
Neurology
Oncology
Prognosis
STAT6 Transcription Factor - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy. MTX was given at a dose of 8.0 g/m 2 for induction and at a dose of 3.5–8.0 g/m 2 for maintenance. There were eight complete responses (CR), one partial response, one stable disease, and six patients whose tumors progressed in spite of the chemotherapy. At final follow-up, five of five CRs were alive and well without radiotherapy, with median follow-up of 26 months. Overall survival in eight non-CRs treated with the subsequent radiotherapy was 36 months. In the immunohistochemical study, STAT6 was positively expressed in 8 out of 13 cases. They included all non-CRs and two CRs. This observation suggests that STAT6 expression can be used as a prognostic determinant for MTX chemotherapy.
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-008-9736-9